(Boursier.com) — The operating loss ofHybrigenics SA was reduced to -0.1 ME in 2021, compared to -0.3 ME during the previous financial year, thanks to the cessation of personnel costs (no more employees in 2021). Operating expenses consist mainly of fees related to the listing of the company on Euronext Growth, the maintenance of the patent portfolio and various legal fees.
The financial result amounts to 0.4 ME, following the sale of Hybrigenics Services shares.
The exceptional result stands at -0.4 ME, following the liquidation of the American subsidiary Hybrigenics Pharma Inc.
The company’s net loss for the year was limited to -0.1 ME, against -0.3 ME a year earlier.
On the liabilities side, corporate equity amounted to €9.4 million at December 31, 2021, compared to €4.9 million at the end of 2020, also under
the effect of the issue of new shares under the financing line.
Hybrigenics SA presents in its balance sheet a financial debt of 1 ME relating to the operation of investment in the company Inoviem Scientific, and a debt with related parties (DMS Group) of 2.5 ME. Supplier debts are limited to 0.2 ME.
Outlook
Hybrigenics SA announced in early 2022 the CE marking and the launch of the marketing of its new medical device, Macrofill vacuum, the first clinical uses of which confirm the technological progress achieved.
This innovative and patented single-use medical device significantly reduces the time it takes to collect large quantities of fat cells and provides the patient with more than 90% engraftment and a major reduction in inflammation.
The turnover of the Stemcis and Adip’Sculpt subsidiaries grew by +44% in the 1st quarter, driven by the first sales of the new device.
With regard to Inoviem Scientific (company accounted for using the equity method), new research contracts were acquired by the company during the 1st quarter. In addition, B Cell Design, acquired by Inoviem Scientific at the end of 2021, is accelerating its growth by positioning itself in the diagnostics market. The antibodies developed by B Cell Design allow market players to follow the evolution of the sector, which is migrating from the classic serum kit to kits containing more sensitive and therefore more reliable synthetic antibodies. This development, initiated by the Chinese market which has banned serum kits on its territory, is gaining the American and European markets. B Cell Design’s technology makes it possible to develop diagnostic kits for a wide variety of conditions such as gluten allergies, viral diseases and certain cancers such as colorectal cancer and HPV papillomavirus.
©2022 Boursier.com